Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sf2aWC Vaccine with/without dmLT for Shigella
NCT03038243Phase 2Withdrawn
- Sponsor
- PATH
- Start
- Aug 2017
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Sf2aWC in shigellosis, sponsored by PATH. Planned start Aug 2017; status: withdrawn.
02
Drugs
Sf2aWC
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT03038243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03038243.